Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2067212 | Cell Biology International | 2009 | 8 Pages |
Abstract
Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biophysics
Authors
B. Karabulut, C. Erten, M.K. Gul, E. Cengiz, B. Karaca, Y. Kucukzeybek, G. Gorumlu, H. Atmaca, S. Uzunoglu, U.A. Sanli, Y. Baran, R. Uslu,